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randomised trials: RAVEL (largely patients with narrow vessels),
and E-SIRIUS and SIRIUS (largely patients with long lesions).
Resource costs of the initial procedures and all subsequent events
were taken from NHS Reference Costs; manufacturers’ list prices
were used for the devices. A utility decrement, based on EQ-5D
data collected in an earlier stent trial, was included for further
revascularisation based on the expected duration of symptoms
prior to re-treatment. Cost-effectiveness is reported in terms of
the incremental cost per additional QALY, and cost-effectiveness
acceptability curves are reported showing the probability of DES
being the more cost-effective at particular threshold values for
an additional QALY. RESULTS: Based on clinical data from
RAVEL the cost per QALY was £30,400. The corresponding
results for SIRIUS and E-SIRIUS were £10,500 and £4,950,
respectively. Sensitivity analysis showed that when the clinically
similar mortality rates observed in the trials were incorpo-
rated into the model, they had a major impact on mean cost-
effectiveness but increased uncertainty. CONCLUSIONS: The
incremental cost per QALY of DES, relative to bare metal stent,
was consistently below £35,000 for all sub-groups. There was
considerable uncertainty surrounding cost-effectiveness suggest-
ing additional research may be appropriate.
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OBJECTIVE: To investigate the cardiovascular risk associ-
ated with pioglitazone monotherapy as compared to insulin
monotherapy in a large retrospective database. METHOD:
Patients ≥ 18 years of age with a diagnosis of type-2 diabetes
and initiated with pioglitazone or insulin monotherapy for at
least 6 months with no cardiovascular events reported at base-
line were selected from GE Medical Systems (GEMS) database
of electronic medical records from physician ofﬁces. Patients pre-
scribed other oral anti-diabetic drugs were excluded. Cardiovas-
cular events included one or more of the following forms of
coronary artery disease: myocardial infarction, angina pectoris,
unstable angina, other ischemic heart disease and surgical pro-
cedures of coronary artery bypass and angioplasty, and conges-
tive heart failure. To avoid selection bias, patients were matched
1 :1 on pioglitazone and insulin using propensity scores. Base-
line demographics and clinical characteristics such as duration
of disease, co-morbidities, medical therapies, and duration of
treatment were included in the propensity score analysis. Logis-
tic regression was used to calculate the odds ratio of the cardio-
vascular event in the follow-up period with treatment as the
factor and signiﬁcant (p < 0.1) baseline characteristics as the
adjusting covariates in the model. RESULTS: A total of 381
patients on pioglitazone monotherapy were compared with an
equal number of patients on insulin monotherapy. The crude car-
diovascular event rate in the pioglitazone group was 1.84% com-
pared with 9.71% in the insulin group (p < 0.001). The hazard
ratio was 0.174 for pioglitazone (95% CI = 0.077, 0.396; p <
0.001). The signiﬁcant risk reduction projected for the pioglita-
zone group could not be completely explained by baseline labo-
ratory measurements of lipids, serum creatinine, systolic and
diastolic blood pressure, or duration of diabetes. CONCLU-
SION: In a retrospective propensity-matched cohort analysis in
patients with type-2 diabetes, patients treated with pioglitazone
monotherapy had a signiﬁcantly lower incidence of cardiovas-
cular events than those taking insulin monotherapy.
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OBJECTIVE: To assess the state of the science of HRQOL
assessment in cancer. METHODS: The US National Cancer
Institute formed the Cancer Outcomes Measurement Working
Group (COMWG) made up of 35 leading experts in the ﬁeld to
review the state of the science of assessing three outcomes
(HRQOL, patient satisfaction, economic burden) in four cancers
(breast, prostate, lung, colorectal) across the continuum of care
(screening/prevention, treatment, survivorship, end of life). In
this presentation, the ﬁndings of the COMWG are evaluated
using the Medical Outcomes Trust Instrument Review Criteria.
RESULTS: The results are as follows: 1) There is currently no
consensus deﬁnition or conceptual model for HRQOL; deve-
loping a stronger theoretical base would improve HRQOL 
measurement and interpretation; 2) While there are now 
well-validated HRQOL instruments, validity can be further
enhanced by an integrated application of the tools from modern
psychometrics—especially item response theory (IRT) model-
ing—survey research, and cognitive psychology; 3) a number of
instruments demonstrate adequate internal reliability according
to classical test theory, but reliability could be evaluated more
precisely at different points along the HRQOL continuum using
IRT approaches; 4) interpretation of HRQOL ﬁndings has ben-
eﬁted from recent research on deﬁning and identifying clinically
important differences in instrument scores; both anchor-based
and distribution-based approaches suggest changes of about 7%
of a scale’s breadth are important to patients and clinicians; 5)
responsiveness of a measure is demonstrated when it is shown
to detect statistically signiﬁcant differences in HRQOL also large
enough to be clinically important; 6) while current measurement
techniques have generally proven feasible and acceptable, IRT-
based computer adaptive testing may signiﬁcantly decrease
respondent burden without sacriﬁcing precision; and 7) for
cross-cultural assessment of HRQOL, several instruments cur-
rently meet minimum criteria. CONCLUSIONS: The current
state of the science of HRQOL assessment in cancer is strong.
Further development of a theoretical base and use of modern
analytic techniques, including IRT, will accelerate progress.
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OBJECTIVES: Given the dramatic increase in the incidence of
melanoma worldwide, accurate assessment of the economic
value of staging and treatment options for melanoma is critically
needed to guide policy making. METHODS: Cost-effectiveness
(CE) evaluations published between 1990 and 2003 of diagnos-
tic procedures and treatments of melanoma were identiﬁed via
systematic searches of MEDLINE® and conference proceedings.
Costs and CE ratios presented in each study were updated to
